Windtree Therapeutics files patent in India for cardiac arrythmia therapy

Windtree Therapeutics (WINT) has filed a national phase patent application with the Indian patent office claiming priority to istaroxime for cardiogenic shock and prevention of arrythmias. Arrythmias are irregular heartbeats that can impact the pumping function of the heart. Patients with heart failure and cardiomyopathy are at risk for arrythmias. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function.